NASDAQ$MURA
Mural Oncology Plc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
MURA reported Q3 2025 a net loss of $30.0M.
For Q3 2025, MURA reported net loss was $30.0M. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Net loss $30.0M.
- MD&A covers R&D, cash runway, and sector-specific risks.
- MD&A covers R&D, cash runway, and sector-specific risks.
Headline financials
Revenue & EPS history
Mural Oncology · Revenue · Quarterly
-$1
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline as the company works toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Clinical or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q3 2025
-9.3%
Avg return
Earnings day
-9.4%
Avg return
5 days after
+5.1%
Avg return
30 days after
23%
3 / 13 earnings
Positive
+14.6%
Q4 2023
Best reaction
-61.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.5% | -0.5% | — | |
| Q2 2025 | -20.2% | -30.3% | -9.2% | |
| Q1 2025 | -4.4% | -4.7% | -10.9% | |
| Q4 2024 | -61.6% | -65.0% | -31.3% | |
| Q3 2024 | -0.9% | -4.8% | +2.3% | |
| Q2 2024 | +1.0% | +4.5% | +0.6% | |
| Q1 2024 | +2.7% | +4.0% | -12.0% | |
| Q4 2023 | +14.6% | +13.2% | -16.7% | |
| Q1 2023 | -10.4% | -7.7% | +27.7% | |
| Q2 2023 | -10.4% | -7.7% | +27.7% | |
| Q3 2022 | -10.4% | -7.7% | +27.7% | |
| Q4 2022 | -10.4% | -7.7% | +27.7% | |
| Q3 2023 | -10.4% | -7.7% | +27.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro